Reactogenicity represents the physical manifestation of the inflammatory response to
vaccination, and can include injection-site pain, redness, swelling or induration at the …

The present rapid growth in the availability of safe and effective vaccines provides a
continuing need to expand and simplify vaccine administration programs. The replacement …

The Global Pertussis Initiative (GPI) was established in 2001 to assess the global extent of
the ongoing problem of pertussis and to evaluate and prioritize pertussis control strategies …

Many countries continue to experience pertussis epidemics despite widespread vaccination.
Waning protection after booster vaccination has highlighted the need for a better …

This module is part of the WHO series The immunological basis for immunization, which was
initially developed in 1993 as a set of eight modules, comprising one module on general …

Reduced-antigen-content diphtheria–tetanus–acellular-pertussis (dTpa) vaccines are
predominantly recommended for once-in-a-lifetime use. A second dTpa (Boostrix™ …

Pertussis, or whooping cough, is an infectious disease that is caused by Bordetella
pertussis, affects all age groups and is vaccine preventable. Recently, an increase in …

Reduced-antigen, combined diphtheria, tetanus and three-component acellular pertussis
vaccine (Tdap; Boostrix®) is indicated for booster vaccination against diphtheria, tetanus …

PURPOSE: Many countries recommend human papillomavirus (HPV) vaccination in female
adolescents at an age when other vaccines are routinely administered. This open …

The immunogenicity and reactogenicity of booster vaccination with GSK Biologicals'
hexavalent DTPa-HBV-IPV/Hib vaccine was assessed in toddlers aged 12–18 months …